lisdexamfetamine CAS: 608137-32-2

CAS NO: 608137-32-2
lisdexamfetamine
Chemical Name: lisdexamfetamine
Molecular Formula: C15H25N3O
Formula Weight: 263.38
CAS No.: 608137-32-2
Description Review
Description

Lisdexamfetamine (CAS: 608137-32-2) is a medication used for the treatment of attention deficit hyperactivity disorder (ADHD) and binge eating disorder (BED). It was first approved by the US Food and Drug Administration (FDA) in 2007 under the brand name Vyvanse, and has since become widely used as a stimulant medication for these conditions. This article will provide an overview of lisdexamfetamine, including its chemical properties, health benefits, potential effects, product mechanism, safety, side effects, dosing information, and a conclusion on its use.

Chemical Properties The chemical name for lisdexamfetamine is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide dimethyl sulfoxide solvate. Its molecular formula is C15H25N3O•C2H6OS, and it has a formula weight of 263.38 g/mol. The CAS number for this compound is 608137-32-2.

Top Ten Keywords/Synonyms

  1. ADHD treatment
  2. Lisdexamfetamine
  3. Stimulant medication
  4. Vyvanse
  5. Binge eating disorder medication
  6. Central nervous system stimulant
  7. Amphetamine derivative
  8. Attention deficit disorder
  9. Hyperactivity treatment
  10. Dextroamphetamine prodrug

Health Benefits Lisdexamfetamine is primarily used for the treatment of ADHD and binge eating disorder. It works by increasing the levels of dopamine and norepinephrine in the brain, which are neurotransmitters that play a key role in regulating attention, impulse control, and appetite. By increasing the levels of these neurotransmitters, lisdexamfetamine can help improve symptoms of ADHD and reduce episodes of binge eating.

Potential Effects In clinical trials, lisdexamfetamine has been shown to be highly effective at improving symptoms of ADHD and reducing episodes of binge eating in patients with BED. It has also been found to be well-tolerated, with few serious side effects reported. Additionally, lisdexamfetamine has demonstrated good pharmacokinetic properties, meaning it is well-absorbed and distributed throughout the body, and is metabolized and eliminated from the body in a predictable manner.

Product Mechanism Lisdexamfetamine is a central nervous system (CNS) stimulant that increases the levels of dopamine and norepinephrine in the brain. Specifically, it is a prodrug of dextroamphetamine, which means that it is converted into dextroamphetamine in the body. Dextroamphetamine is a CNS stimulant that increases the release of dopamine and norepinephrine from nerve endings in the brain, thereby improving attention, focus, and impulse control.

Safety Overall, lisdexamfetamine has been found to be safe and well-tolerated in clinical trials. However, like all medications, it does carry some risks of side effects and adverse events. Patients taking lisdexamfetamine should be monitored regularly for any signs of cardiac dysfunction, psychiatric symptoms, or other serious side effects.

Side Effects Some of the most common side effects reported with lisdexamfetamine include dry mouth, insomnia, irritability, and decreased appetite. These side effects are usually mild to moderate in severity and go away on their own over time. More serious side effects, such as cardiovascular events or psychotic symptoms, are rare but can occur in some patients.

Dosing Information Lisdexamfetamine is typically taken orally, either with or without food. The recommended dose for patients with ADHD is 30 mg once daily in the morning. For patients with BED, the starting dose is 30 mg once daily in the morning, with the option to increase the dose by 20 mg per week up to a maximum of 70 mg/day. Patients should follow their healthcare provider's instructions carefully when taking this medication.

Conclusion Lisdexamfetamine is a highly effective and well-tolerated medication used for the treatment of ADHD and binge eating disorder. As a CNS stimulant, it increases the levels of dopamine and norepinephrine in the brain, thereby improving attention, focus, and impulse control. While it does carry some risks of side effects and adverse events, overall, it has been found to be safe and effective in clinical trials. Patients taking lisdexamfetamine should work closely with their healthcare providers to ensure proper dosing and monitoring for any potential side effects

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code